Eupraxia Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 31 Dec 2025
Net Income -$38.6MTTM through 31 Dec 2025
Free Cash Flow -$28.6MTTM through 31 Dec 2025
Margins
| Current |
|---|
Returns
-47.0%ROE
-44.8%ROA
Balance Sheet Health
Current Ratio15.12x
Cash & Equivalents$80.6M
Quality Metrics
Altman Z-Score56.51
Piotroski F-Score3 / 9
Earnings-Beat Rate33.3%
Dividend
No dividend
Capital Allocation
R&D Spend$21.3M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.